ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2441

Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis

Alan M. Rosenberg1, Walter Maksymowych2, Yuan Gui3 and Anthony Marotta3, 1Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Augurex Life Sciences Corp., Vancouver, BC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: diagnosis, juvenile idiopathic arthritis-enthesitis (ERA) and polyarthritis, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile
Idiopathic Arthritis (JIA) is a collective term used to denote clinically
discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis,
Polyarthritis, Psoriatic arthritis, Systemic arthritis and unclassified
arthritis. Polyarthritis is further categorized according to rheumatoid factor
(RF) status. The International League of Associations for Rheumatology (ILAR)
has devised classification criteria of JIA with specific exclusion criteria and
its diagnosis is reliant upon clinical symptoms. While laboratory tests like
CBC, CRP, ESR, RF, ANA, and anti-CCP add prognostic value, they have limited
utility for diagnosis. Thus, markers that can assist in sub-typing JIA at
presentation are imperative as this can influence patient management strategy.
14-3-3η is a joint derived, rheumatoid arthritis (RA) specific marker that
informs radiographic damage. The purpose of this study was to examine the
expression of 14-3-3η in the sub-types of JIA, and to assess whether a relationship
existed between 14-3-3η and RF+ polyarthritis.

Methods:
14-3-3η serum levels were measured in 60 JIA patients as shown in Table 1.
One-way ANOVA analysis was used to determine if group differences existed.
14-3-3η positivity was defined using the adult RA diagnostic cut-off of
≥0.19 ng/ml. The Fisher’s Exact test was employed to assess the
relationship between RF and 14-3-3η positivity in polyarthritis patients.

Results:
ANOVA analysis revealed differences in 14-3-3η serum levels between the
groups. Patients with RF positive polyarticular disease had significantly
higher serum 14-3-3η levels than the other groups. 14-3-3η positivity
analysis revealed that 30% of the oligoarthritis, 53% of RF negative
polyarticular, 50% of psoriatic and 57% of patients with systemic arthritis
were positive for 14-3-3η. Although there were only four patients in the
enthesitis group, none of them were 14-3-3η positive. Fisher’s Exact
testing returned no significant association between RF and 14-3-3η
positive status (p-value = 0.35) indicating that the two markers may uniquely
inform patient profiles within subtypes of JIA, especially since 53% of RF
negative polyarticular JIA patients had positive 14-3-3η tests. 

 

Enthesitis

Oligo

Poly, RF-

Poly, RF+

Psoriatic

Systemic

# of Pts

4

21

19

7

2

7

Median

(QR)

0.06

(0.02-0.09)

0.10

(0.02-0.23)

0.19

(0.02-0.33)

1.83

(0.09-10.59)

0.20

(0.01-0.38)

0.20

(0.01-1.54)

Mean (SD)

0.06 (0.04)

0.23 (0.35)

0.29 (0.38)

4.69 (6.51)

0.20 (0.26)

0.55 (0.69)

% Positivity (n)

0% (0)

30% (7)

53% (10)

71% (5)

50% (1)

57% (4)

ANOVA

p=0.0008

 

Conclusion: 14-3-3η is a joint-derived mechanistic marker that up-regulates
factors that are involved in joint damage pathogenesis. While RF+ polyarthritis
patients had higher 14-3-3η levels, in JIA, 14-3-3η expression has no
significant association with RF positivity and may provide insights into
biochemical processes that uniquely inform JIA sub-typing. 


Disclosure: A. M. Rosenberg, None; W. Maksymowych, Augurex Life Sciences, 5; Y. Gui, Augurex Life Sciences Corp, 3; A. Marotta, Augurex Life Sciences Corp, 3.

To cite this abstract in AMA style:

Rosenberg AM, Maksymowych W, Gui Y, Marotta A. Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-14-3-3-is-present-in-jia-and-is-not-associated-with-rf-polyarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-14-3-3-is-present-in-jia-and-is-not-associated-with-rf-polyarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology